L
Liekele E. Oostenbrug
Publications - 8
Citations - 415
Liekele E. Oostenbrug is an academic researcher. The author has contributed to research in topics: Neoadjuvant therapy & Chemoradiotherapy. The author has an hindex of 5, co-authored 8 publications receiving 309 citations.
Papers
More filters
Journal ArticleDOI
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
Bo Jan Noordman,Manon C.W. Spaander,Roelf Valkema,Bas P. L. Wijnhoven,Mark I. van Berge Henegouwen,Joel Shapiro,Katharina Biermann,Ate van der Gaast,Richard van Hillegersberg,Maarten C.C.M. Hulshof,Kausilia K. Krishnadath,Sjoerd M. Lagarde,Grard A. P. Nieuwenhuijzen,Liekele E. Oostenbrug,Peter D. Siersema,Peter D. Siersema,Erik J. Schoon,Meindert N. Sosef,Ewout W. Steyerberg,Ewout W. Steyerberg,J. Jan B. van Lanschot,Michael Doukas,Nanda C. Krak,Jan-Werner Poley,Caroline M. van Rij,Jaques Jghm Bergman,Suzanne S. Gisbertz,Hanneke W. M. van Laarhoven,Sybren L. Meijer,Lucas Goense,Nadia Haj Mohammad,Monique G.G. Hobbelink,G. Johan A. Offerhaus,Frank P. Vleggaar,Wouter L. Curvers,Geert-Jan Creemers,Mark J. Roef,Maurice J.C. van der Sangen,Jeroen Buijsen,Robert G. Riedl,Wendy M. J. Schreurs,Fabiënne A. R. M. Warmerdam,Mjr Janssen,Chella Van Der Post,Sandra A Radema,Camiel Rosman,H.J.T. Rutten +46 more
TL;DR: The correlation between clinical response during clinical response evaluations and the final pathological response in resection specimens was shown, as shown by the proportion of tumour regression grade (TRG) 3 or 4 residual tumours that was missed duringclinical response evaluations.
Journal ArticleDOI
Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
Marieke J H Coenen,Dirk J. de Jong,Corine van Marrewijk,Luc J J Derijks,Sita H. Vermeulen,Dennis R Wong,Olaf H. Klungel,André L. M. Verbeek,P. M. Hooymans,Wilbert H.M. Peters,Rene H. M. te Morsche,William G. Newman,Hans Scheffer,Henk-Jan Guchelaar,Barbara Franke,Ad A.M. Masclee,Marieke Pierik,Wout G.N. Mares,W. Hameeteman,Peter J. Wahab,H. Seinen,M.C.M. Rijk,I.M. Harkema,M. de Bièvre,Liekele E. Oostenbrug,Christian Bakker,Michel Aquarius,C. van Deursen,A.B. van Nunen,J.G. Goedhard,M. Hamacher,I.A.M. Gisbertz,B.J. Brenninkmeijer,A.C.I.T.L. Tan,M.N. Aparicio-Pagés,Ellen M. Witteman,S.A.C. van Tuyl,Ronald Breumelhof,Arnold Stronkhorst,L.P.L. Gilissen,Erik J. Schoon,J.W.M. Tjhie-Wensing,A. Temmerman,Jan Nicolai,J. D. van Bergeijk,D.J. Bac,Ben J.M. Witteman,Nofel Mahmmod,J.J. Uil,H. Akol,R.J.T. Ouwendijk,I.P. van Munster,Maartje Pennings,A.M.P. De Schryver,T.J.M. van Ditzhuijsen,Robert C.H. Scheffer,Tessa E H Römkens,D.L. Schipper,Paul J Bus,Jan-Willem Straathof,M.L. Verhulst,P.J. Boekema,J.T. Kamphuis,H.J. van Wijk,J.M.J.L. Salemans,J.R. Vermeijden,S.D.J. van der Werf,R.J. Verburg,P. Spoelstra,J.M.L. de Vree,K. van der Linde,H.J.A. Jebbink,M. Jansen,H. Holwerda,N. van Bentem,J.J. Kolkman,Maurice G. Russel,G.H. van Olffen,M.J. Kerbert-Dreteler,Marloes Bargeman,J.M. Götz,R. Schröder,Jeroen M. Jansen,L. P. Bos,Leopold G.J.B. Engels,Mariëlle Romberg-Camps,Eric T.P. Keulen,A.A.J. van Esch,Joost P.H. Drenth,M.C.A. van Kouwen,Geert J. A. Wanten,T.J. Bisseling,M.W.J. van Vugt,P. C. van de Meeberg,S.J. van den Hazel,W.N.H.M. Stuifbergen,M.J.A.L. Grubben,U. de Wit,G.A.H. Dodemont,R.F. Eichhorn,J. M. H. Van den Brande,Anton H. Naber,E.J. van Soest,Paul J. Kingma,N.C. Talstra,K.F. Bruin,F.H.J. Wolfhagen,Daan W. Hommes,P. P. J. Van Der Veek,J.C.A. Hardwick,R.J. Stuyt,Herma H. Fidder,Bas Oldenburg,T.G. Tan +113 more
TL;DR: Screening for variants in TPMT did not reduce the proportions of patients with hematologic ADRs during thiopurine treatment for IBD, but there was a 10-fold reduction in hematological ADRs among variant carriers who were identified and received a dose reduction, compared with variant carriersWho did not, without differences in treatment efficacy.
Journal ArticleDOI
Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Propensity Matched Study
Berend J van der Wilk,Bo Jan Noordman,Lisanne K A Neijenhuis,Daan Nieboer,Grard A. P. Nieuwenhuijzen,Meindert N. Sosef,Mark I. van Berge Henegouwen,Sjoerd M. Lagarde,Manon C.W. Spaander,Roelf Valkema,Katharina Biermann,Bas P. L. Wijnhoven,Ate van der Gaast,J. Jan B. van Lanschot,Michael Doukas,Suzan Nikkessen,Misha D. P. Luyer,Erik J. Schoon,Mark J. Roef,Ineke van Lijnschoten,Liekele E. Oostenbrug,Robert G. Riedl,Suzanne S. Gisbertz,Kausilia K. Krishnadath,Roel J. Bennink,Sybren L. Meijer +25 more
TL;DR: In this retrospective study, OS and PFS in patients with cCR undergoing active surveillance or immediate surgery were not significantly different and active surveillance with postponed surgery for recurrent disease was not associated with a higher distant dissemination rate or more severe adverse postoperative outcomes.
Journal ArticleDOI
Interobserver Reproducibility of Diffusion-Weighted MRI in Monitoring Tumor Response to Neoadjuvant Therapy in Esophageal Cancer
Robert M. Kwee,Alexander K. Dik,Meindert N. Sosef,Ralph C. M. Berendsen,Sander Sassen,Guido Lammering,Ruud Clarijs,Liekele E. Oostenbrug,Rachel L. G. M. Blom,Roy F. A. Vliegen +9 more
TL;DR: Semi-automated volumetric ADC measurements have higher reproducibility than manual ADC measurements in assessing tumor response to chemoradiotherapy in patients with esophageal adenocarcinoma.
Journal ArticleDOI
Endoscopic ultrasound measurements for detection of residual disease after neoadjuvant chemoradiotherapy for esophageal cancer.
Ruben D. van der Bogt,Bo Jan Noordman,Kausilia K. Krishnadath,Carlijn A. Roumans,Erik J. Schoon,Liekele E. Oostenbrug,Peter D. Siersema,Frank P. Vleggaar,J. Jan B. van Lanschot,Manon C.W. Spaander +9 more
TL;DR: EUS measurements of residual thickness and residual area adequately detected TRG3 - 4 residual disease with a sensitivity of almost 90 % 12 weeks after completion of nCRT, and may aid in the restaging of esophageal cancer after n CRT.